Released Nov 13, 2025, before the open
10-Q filed Nov 13, 2025, 44 days after period end · 0001193125-25-279096
Q3 2025 · 10-Q
Revenue$1.74M$1.74M −43.4% vs Q3 2024−8.7% vs Q2 2025
Net Income-$32.25M-$32.25M N/M vs Q3 2024N/M vs Q2 2025
EPS Diluted-$0.27-$0.27 N/M vs Q3 2024N/M vs Q2 2025
Operating Income-$34,735,000N/M
Operating Cash Flowderived-$24,374,000N/M
Free Cash Flowderived-$26,577,000N/M
Margins · derived
Operating margin-1995.1%−291.2 pt vs Q3 2024
Net margin-1852.4%−301.4 pt vs Q3 2024
What the release said
The release
Same quarter
| Metric | Q3 2025 | Q3 2024 | Q3 2023 | Q3 2022 |
|---|---|---|---|---|
| Revenue | $1.74M | $3.07M | $1.94M | $14.98M |
| Net Income | -$32.25M | -$47.68M | -$45.17M | -$83.56M |
| EPS Diluted | -$0.27 | -$0.40 | -$0.46 | -$0.86 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR